Head-to-head · WeighScore
FuturHealth vs Get Thin MD
The verdict
Get Thin MD takes it — 66.7/100 to 65.6/100, but only just.
Get Thin MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Get Thin MD is a nationwide async telehealth platform offering compounded semaglutide and tirzepatide injections plus brand-name Ozempic and Zepbound where appropriate, alongside a broader wellness menu… FuturHealth is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FuturHealth | Get Thin MD |
|---|---|---|
| WeighScore | 65.6/100 | 66.7/100 |
| Grade | C | C |
| Scorecard rank | #215 | #179 |
| Semaglutide | $199/mo (compounded) | $199/mo (compounded) |
| Tirzepatide | Not disclosed | $299/mo (compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #215 · C
Strengths
- LegitScript Certified and HITRUST Certified
- Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
- Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths
Where it loses points
- Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- BBB complaints describe recurring charges without medication received — confirm cancellation flow first
- Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
- Pricing not shown until after the qualification questionnaire or portal login
- Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Graded #179 · C
Strengths
- 3-month compounded semaglutide at $169/mo is among the lowest ongoing prices in the category
- Price-lock promise — same price every dose, no hidden fees
- Both compounded and brand-name options on one platform (sema, tirz, plus Ozempic and Zepbound)
- Nationwide availability with async evaluation — no in-person visit
- Broader wellness menu (sermorelin, NAD+, HRT, hair loss) lets you consolidate protocols
Where it loses points
- Compounded medications aren't FDA-approved and lack the review of brand-name GLP-1s
- Pharmacy partners not named — no way to verify the compounding source or batch testing
- Claims nationwide coverage but publishes no state list — confirm at intake
- Headline results (9.6 lbs in 30 days) come from self-reported patient data, not a trial
- Wide wellness funnel may steer you toward non-weight-loss protocols
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.